INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51501, 13292, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51502, 17981, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51503, 17982, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51504, 17983, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51505, 17984, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51506, 17985, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51507, 18952, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51508, 18953, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51509, 18955, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51510, 30532, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51511, 4802, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51512, 13291, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51513, 13292, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51514, 17981, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51515, 17982, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51516, 17983, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51517, 17984, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51518, 17985, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51519, 18952, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51520, 18953, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51521, 18955, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51522, 30532, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51523, 4802, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51524, 13291, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51525, 13292, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51526, 17981, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51527, 17982, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51528, 17983, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51529, 17984, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51530, 17985, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51531, 18952, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51532, 18953, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51533, 18955, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51534, 30532, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51535, 4802, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51536, 13291, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51537, 13292, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51538, 17981, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51539, 17982, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51540, 17983, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51541, 17984, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51542, 17985, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51543, 18952, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51544, 18953, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51545, 18955, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51546, 30532, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hilgenberg JC, Johantgen WC "Bradycardia after intravenous fentanyl during subarachnoid anesthesia." Anesth Analg 59 (1980):  162-3|Blair JR, Pruett JK, Crumrine RS, Balser JJ "Prolongation of QT interval in association with the administration of large doses of opiates." Anesthesiology 67 (1987):  442-3|Sebel PS, Bovill JG, Boekhorst RA, Rog N "Cardiovascular effects of high-dose fentanyl anaesthesia." Acta Anaesthesiol Scand 26 (1982):  308-15|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Heaney RM "Left bundle branch block associated with propoxyphene hydrochloride poisoning." Ann Emerg Med 12 (1983):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51547, 4838, 'Ferrous sulfate anhydrous', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51548, 4838, 'Ferrous sulfate anhydrous', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51549, 4838, 'Ferrous sulfate anhydrous', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51550, 0, 'Ferric carboxymaltose', 'Hypertension', 'Transient elevation of blood pressure has been reported in clinical trials in patients receiving ferric carboxymaltose.  These elevations generally occurred immediately after dosing and resolved in 30 minutes.  Patients should be monitored for symptoms or signs of hypertension following treatment.', '2', '"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51551, 0, 'Ferric carboxymaltose', 'Hypophosphatemia', 'Patients with malabsorption of fat-soluble vitamins or phosphate, or using medications affection proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, or malnutrition may experience symptomatic hypophosphatemia.  Cases occur mostly after repeat exposure.  Most cases resolved within 3 months.  Monitor serum phosphate in at risk patiens requiring repeat treatment.', '2', '"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51552, 0, 'Ferric carboxymaltose', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):|"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51553, 4838, 'Ferrous fumarate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51554, 4838, 'Ferrous fumarate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51555, 4838, 'Ferrous fumarate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51556, 0, 'Ferric derisomaltose', 'Iron Overload', 'Ferric derisomaltose should not be administered to patients with iron overload.', '2', '"Product Information. Monoferric (ferric derisomaltose)." Pharmacosmos Therapeutics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51557, 4866, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51558, 19040, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51559, 22859, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51560, 23699, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51561, 25330, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51562, 25372, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51563, 25399, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51564, 25403, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51565, 26382, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51566, 33561, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51567, 4866, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51568, 19040, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51569, 22859, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51570, 23699, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51571, 25330, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51572, 25372, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51573, 25399, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51574, 25403, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51575, 26382, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51576, 33561, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51577, 0, 'Ferumoxytol', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):|"Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51578, 0, 'Ferumoxytol', 'Hypotension', 'Clinically significant hypotension has been reported in clinical trials and postmarketing after the administration of ferumoxytol injection.  Patients should be monitored for signs and symptoms of hypotension after administration.', '2', '"Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51579, 0, 'Fibrinogen human', 'Thromboembolism', 'Thrombotic events have been reported in patients receiving human fibrinogen concentrate.  Treatment with human fibrinogen concentrate has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL, and the risk may be greater when the target fibrinogen plasma level is 150 mg/dL.  Weigh the benefits of fibrinogen administration versus the risks of thrombosis.  Patients receiving fibrinogen should be monitored for signs and symptoms of thrombosis.  Inform patients that blood clots with or without consequent obstruction of blood flow may occur and that any symptoms of blood clots (unexplained chest and/or leg pain or swelling of the legs or arms, coughing up blood, shortness of breath, increased rate of breathing or unexplained symptoms related to the nervous system such as stroke or weakness) should be reported to their physician immediately.', '2', '"Product Information. RiaSTAP (fibrinogen)." CSL Behring LLC  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51580, 0, 'Aminophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51581, 0, 'Aminophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'Reidenberg MM, Restivo K "The binding of theophylline to serum proteins of hemodialysis patients." J Dial 3 (1979):  375-81|Bauer LA, Bauer SP, Blouin RA "The effect of acute and chronic renal failure on theophylline clearance." J Clin Pharmacol 22 (1982):  65-8|Shaw LM, Fields L, Mayock R "Factors influencing theophylline serum protein binding." Clin Pharmacol Ther 32 (1982):  490-6|Leakey TE, Elias-Jones AC, Coates PE, Smith KJ "Pharmacokinetics of theophylline and its metabolites during acute renal failure: a case report." Clin Pharmacokinet 21 (1991):  400-8|Nicot G, Charmes JP, Lachatre G, et al. "Theophylline toxicity risks and chronic renal failure." Int J Clin Pharmacol Ther Toxicol 27 (1989):  398-401|Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988):  996-1004|Leopold D, Webb D, Buss DC, Fifield RA, Smith AP, Routledge PA "The ex vivo plasma protein binding of theophylline in renal disease." Br J Clin Pharmacol 19 (1985):  823-5|Kraan J, Jonkman JH, Koeter GH, et al. "The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease." Eur J Clin Pharmacol 35 (1988):  357-62', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51582, 0, 'Aminophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Nakada T, Kwee IL, Lerner AM, Remler MP "Theophylline-induced seizures: clinical and pathophysiologic aspects." West J Med 138 (1983):  371-4|Aderka D, Shavit G, Garfinkel D, et al. "Life-threatening theophylline intoxication in a hypothyroid patient." Respiration 44 (1983):  77-80|Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985):  411-5|Bahls FH, Ma KK, Bird TD "Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults." Neurology 41 (1991):  1309-12|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Stewart JT "Prolongation of ECT-induced seizures with theophylline." J Am Geriatr Soc 44 (1996):  475', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51583, 0, 'Aminophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51584, 0, 'Aminophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Levy G, Gibson TP, Whitman W, Procknai J "Hemodialysis clearance of theophylline." JAMA 237 (1977):  1466-7|Lee CS, Marbury TC, Perrin JH, Fuller TJ "Hemodialysis of theophylline in uremic patients." J Clin Pharmacol April (1979):  219-26|Kradjan WA, Martin TR, Delaney CJ, et al. "Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure." Nephron 32 (1982):  40-4|Anderson JR, Poklis A, McQueen RC, Purtell JN, Slavin RG "Effects of hemodialysis on theophylline kinetics." J Clin Pharmacol 23 (1983):  428-32|Lee CS, Peterson JC, Marbury TC "Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis." J Clin Pharmacol 23 (1983):  274-80|Vaziri ND, Barton CH, Ness R, Clark D "Dialysability of theophylline." J Dial 2 (1978):  243-9|Slaughter RL, Green L, Kohli R "Hemodialysis clearance of theophylline." Ther Drug Monit 4 (1982):  191-3|Blouin RA, Bauer LA, Bustrack JA, Record KE, Bivins BA "Theophylline hemodialysis clearance." Ther Drug Monit 2 (1980):  221-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51585, 0, 'Aminophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'Hendeles L, Weinberger M, Johnson G "Monitoring serum theophylline levels." Clin Pharmacokinet 3 (1978):  294-312|Sessler CN "Theophylline toxicity: clinical features of 116 consecutive cases." Am J Med 88 (1990):  567-76|Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO "Inpatient theophylline toxicity: preventable factors." Ann Intern Med 114 (1991):  748-53|Marchlinski FE, Miller JM "Atrial arrhythmias exacerbated by theophylline: response to verapamil and evidence for triggered activity in man." Chest 88 (1985):  931-4|Levine JH, Michael JR, Guarnieri T "Multifocal atrial tachycardia: a toxic effect of theophylline." Lancet 1 (1985):  12-4|Taniguchi A, Ohe T, Shimorura K "Theophylline-induced ventricular tachycardia in a patient with chronic lung disease: sensitivity to verapamil." Chest 96 (1989):  958-9|Bittar G, Friedman HS "The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants." Chest 99 (1991):  1415-20|Patel AK, Skatrud JB, Thomsen JH "Cardiac arrhythmias due to oral aminophylline in patients with chronic obstructive pulmonary disease." Chest 80 (1981):  661-5|Albert S "Aminophylline toxicity." Pediatr Clin North Am 34 (1987):  61-73|Milgrom H, Bender B "Current issues in the use of theophylline." Am Rev Respir Dis 147 (1993):  s33-9|Chazan R, Karwat K, Tyminska K, Tadeusiak W, Droszcz W "Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction." Int J Clin Pharmacol Ther 33 (1995):  170-5|Mccarthy M "Theophylline, beta-agonists, and cardiovascular death." Lancet 349 (1997):  33', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51586, 0, 'Ferumoxides', 'Anaphylaxis', 'The possibility of a reaction including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions should always be considered when using ferumoxides.  Increased risk is associated with a known sensitivity to iron or dextran, history of previous reaction to a radiographic contrast agent, known allergies, other hypersensitivities, and underlying immune disorders, autoimmunity or immunodeficiencies that predispose to specific or non specific mediator release.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51587, 0, 'Ferumoxides', 'Autoimmune Diseases', 'Ferumoxides has not been studied in patients with immune disease, but a high rate of adverse reactions to injectable iron formulations have been reported in the published literature.  Caution is advised.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51588, 0, 'Ferumoxides', 'Iron Overload', 'Ferumoxides which contains iron, should be used with caution in patients with disorders associated with iron over load (e.g., hemosiderosis, chronic hemolytic anemia with frequent blood transfusions).', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51589, 19888, 'Ferrous gluconate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', '"Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc|"Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51590, 19888, 'Ferrous gluconate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51591, 19888, 'Ferrous gluconate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', '"Product Information. Feosol (ferrous sulfate)." SmithKline Beecham|"Product Information. Ferrous Gluconate (ferrous gluconate)." Paddock Laboratories Inc  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51592, 14760, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51593, 14761, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51594, 20038, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51595, 20039, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51596, 14760, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51597, 14761, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51598, 20038, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51599, 20039, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51600, 14760, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51601, 14761, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51602, 20038, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51603, 20039, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51604, 14760, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51605, 14761, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51606, 20038, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51607, 20039, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51608, 14760, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51609, 14761, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51610, 20038, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51611, 20039, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51612, 14760, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51613, 14761, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51614, 20038, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51615, 20039, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', '"Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51616, 0, 'Flecainide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975):  669-76|Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975):  335-9|Ravid S, Podrid PJ, Lampert S, Lown B "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol 14 (1989):  1326-30|Swiryn S, Kim SS "Quinidine-induced syncope." Arch Intern Med 143 (1983):  314-6|Gottlieb SS, Packer M "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J 118 (1989):  611-2|Ochs HR, Grube E, Greenblatt DJ, Arendt R "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol 19 (1981):  173-6|Prescott LF, Adjepon-Yamoah KK, Talbot RG "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J 1 (1976):  939-41|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med 78 (1973):  499-508|Singh SN, Fletcher RD, Fisher SG, et al. "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med 333 (1995):  77-82|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51617, 0, 'Flecainide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'Anderson JL, Popat KD "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy." Arch Intern Med 141 (1981):  801-2|Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J "Amiodarone-induced polymorphous ventricular tachycardia." Am Heart J 105 (1983):  6-12|Strasberg B, Sclarovsky S, Erdberg A, et al. "Procainamide-induced polymorphous ventricular tachycardia." Am J Cardiol 47 (1981):  1309-14|Stratmann H, Walter K, Kennedy H "Torsade de pointes associated with elevated N-acetylprocainamide levels." Am Heart J 109 (1985):  375-6|Lo KS, Gantz KB, Stetson PL, et al. "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980):  413-4|Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990):  1146|Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980):  665-8|Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981):  946-7|Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982):  110-4|Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983):  870-1|Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990):  342-3|Cocco G, Strozzi C, Chu D, Pansini R "Torsades de pointes as a manifestation of mexiletine toxicity." Am Heart J 100 (1980):  878-80|Nora MO, Chandrasekaran K, Hammill SC, Reeder GS "Prolongation of ventricular depolarization: ECG manifestation of mexiletine toxicity." Chest 95 (1989):  925-8|Morganroth J, Pratt CM "Prevalence and characteristics of proarrhythmia from moricizine (themozine)." Am J Cardiol 63 (1989):  172-6|Damle R, Levine J, Matos J, et al. "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia." Ann Intern Med 116 (1992):  375-81|Nathan AW, Hellestrand KJ, Bexton RS, Camm AJ "Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent." Postgrad Med J 60 (1984):  155-6|Stavens CS, McGovern B, Garan H, Ruskin JN "Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone." Am Heart J 110 (1985):  24-9|Hii JT, Wyse DG, Gillis AM, et al. "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991):  1568-70|Cheesman M, Ward DE "Exacerbation of ventricular tachycardia by tocainide." Clin Cardiol 8 (1985):  47-50|Bauman JL, Bauernfeind RA, Hoff JV, et al. "Torsade de pointes due to quinidine: observations in 31 patients." Am Heart J 107 (1984):  425-30|Koenig W, Schinz AM "Spontaneous ventricular flutter and fibrillation during quinidine medication." Am Heart J 105 (1983):  863-5|Morganroth J, Horowitz LN "Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias." Am J Cardiol 56 (1985):  585-7|Au PK, Bhandari AK, Bream R, et al. "Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia." J Am Coll Cardiol 9 (1987):  389-97|Engler RL, LeWinter M "Tocainide-induced ventricular fibrillation." Am Heart J 101 (1981):  494-6|Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992):  794-6|Orebaugh SL, Handy M "Intravenous adenosine therapy accelerating rate of paroxysmal supraventricular tachycardia." Am J Emerg Med 10 (1992):  326-30|Reed R, Falk JL, O''Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991):  566-70|Meurer MK "A 21-year-old woman with rapid atrial fibrillation after adenosine administration." J Emerg Nurs 17 (1991):  135-6|Dougherty AH, Gilman JK, Wiggins S, Jalal S, Naccarelli GV "Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine." Pacing Clin Electrophysiol 16 (1993):  8-12|"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985):  675-90|Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985):  424-8|Sulke AN, Holt P, Sowton GE "Acceleration of conduction within an accessory pathway with propafenone." Int J Cardiol 28 (1990):  105-7|"Product Information. Adenocard (adenosine)." Fujisawa  (2001):|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993):  2701-2|Said SAM, Somer ST, Luttikhuis HAO "Flecainide-induced JT prolongation, t wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation." Int J Cardiol 44 (1994):  285-7|Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993):  2590-7|"Product Information. Norpace (disopyramide)." Searle  (2001):|Oberg KC, Otoole MF, Gallastegui JL, Bauman JL "''''late'''' proarrhythmia due to quinidine." Am J Cardiol 74 (1994):  192-4|Romer M, Candinas R "Adenosine-induced non-sustained polymorphic ventricular tachycardia." Eur Heart J 15 (1994):  281-2|Hohnloser SH, Klingenheben T, Singh BN "Amiodarone-associated proarrhythmic effects - a review with special reference to torsade de pointes tachycardia." Ann Intern Med 121 (1994):  529-35|Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994):  1814-7|Exner DV, Muzyka T, Gillis AM "Proarrhythmia in patients with the Wolff-Parkinson-White Syndrome after standard doses of intravenous adenosine." Ann Intern Med 122 (1995):  351-2|Williamson BD, Hummel J, Niebauer M, Man C, Strickberger SA, Daoud E, Morady F "Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction." Am Heart J 130 (1995):  399-401|Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995):  94-101|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|Hohnloser SH, Vandeloo A, Baedeker F "Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine." J Am Coll Cardiol 26 (1995):  852-8|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):|Silverman AJ, Machado C, Baga JJ, Meissner MD, Lehmann MH, Steinman RT "Adenosine-induced atrial fibrillation." Am J Emerg Med 14 (1996):  300-1|Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, Capucci A, Magnani B "Ventricular fibrillation after intravenous amiodarone in wolff-parkinson-white syndrome with atrial fibrillation." Am Heart J 131 (1996):  1214-6|Faggiano P, Gardini A, Daloia A, Benedini G, Giordano A "Torsade de pointes occurring early during oral amiodarone treatment." Int J Cardiol 55 (1996):  205-8|Heisler BE, Ferrier GR "Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion." J Pharmacol Exp Ther 279 (1996):  317-24|Strickberger SA, Man KC, Daoud EG, et al. "Adenosine-induced atrial arrhythmia: a prospective analysis." Ann Intern Med 127 (1997):  417-22', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51618, 0, 'Flecainide', 'Sick Sinus Syndrome', 'The use of flecainide is contraindicated in patients with cardiogenic shock, second- or third-degree AV block or right bundle-branch block when associated with a left hemiblock(bifascicular block) in the absence of a functional artificial pacemaker, or congenital QT prolongation.  Therapy with flecainide should be administered with extreme caution in patients with sick sinus syndrome or bradycardia-tachycardia syndrome due to the risk of sinus bradycardia, pause or arrest.', '3', 'Forbes WP, Hee TT, Mohiuddin SM, Hillman DE "Flecainide-induced cardiogenic shock." Chest 94 (1988):  1121|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51619, 0, 'Flecainide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', '"Product Information. Tonocard (tocainide)." Merck & Co., Inc  (2002):|"Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals  (2002):|"Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals  (2002):|"Product Information. Procan SR (procainamide)." Parke-Davis  (2001):|"Product Information. Pronestyl (procainamide)." Apothecon Inc  (2001):|"Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):|"Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim  (2001):|"Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company|"Product Information. Norpace (disopyramide)." Searle  (2001):|"Product Information. Cordarone (amiodarone)." Apothecon Inc  (2022):|"Product Information. Corvert (ibutilide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51620, 0, 'Flecainide', 'Liver Diseases', 'Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks.  If used, frequent and early plasma level monitoring is required to guide dosage.  Additionally, dosage increases should be made very cautiously when plasma levels have plateaued (after more than four days).', '2', 'McQuinn RL, Pentikainen PJ, Chang SF, Conrad GJ "Pharmacokinetics of flecainide in patients with cirrhosis of the liver." Clin Pharmacol Ther 44 (1988):  566-72|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51621, 0, 'Flecainide', 'Kidney Diseases', 'Flecainide is primarily eliminated by the kidney.  Approximately 30% (10% to 50%) of flecainide is excreted in the urine unchanged.  The serum concentration of flecainide is increased and the half-life prolonged in patients with renal impairment.  Rare conditions such as a strict vegetarian diet or renal tubular acidosis that significantly increase the urinary pH slow the urinary elimination of flecainide.  Adjustment of dosage is necessary and modification should be based on the degree of renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'Williams AJ, McQuinn RL, Walls J "Pharmacokinetics of flecainide acetate in patients with severe renal impairment." Clin Pharmacol Ther 43 (1988):  449-55|Hertrampf R, Gundert-Remy U, Beckmann J, et al. "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991):  61-3|Forland SC, Burgess E, Blair AD, et al. "Oral flecainide pharmacokinetics in patients with impaired renal function." J Clin Pharmacol 28 (1988):  259-67|Braun J, Kollert JR, Becker JU "Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function." Eur J Clin Pharmacol 31 (1987):  711-4|Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chiolero R "Hemofiltration clearance of flecainide in a patient with acute renal failure." Intensive Care Med 14 (1988):  236-7|Bailie GR, Waldek S "Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis." J Clin Pharm Ther 13 (1988):  121-4|Forland SC, Cutler RE, McQuinn RL, Kvam DC, Miller AM, Conard GJ, Parish S "Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function." J Clin Pharmacol 28 (1988):  727-35|Ziegelbaum M, Lever H "Acute urinary retention associated with flecainide." Cleve Clin J Med 57 (1990):  86-7|"Product Information. Tambocor (flecainide)." 3M Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51622, 13308, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51623, 19035, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51624, 19670, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51625, 21172, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51626, 23445, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51627, 23641, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51628, 23642, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51629, 29848, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51630, 29849, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51631, 13308, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51632, 19035, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51633, 19670, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51634, 21172, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51635, 23445, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51636, 23641, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51637, 23642, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51638, 29848, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51639, 29849, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51640, 13308, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51641, 19035, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51642, 19670, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51643, 21172, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51644, 23445, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51645, 23641, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51646, 23642, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51647, 29848, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51648, 29849, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51649, 13308, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51650, 19035, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51651, 19670, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51652, 21172, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51653, 23445, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51654, 23641, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51655, 23642, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51656, 29848, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51657, 29849, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51658, 13308, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51659, 19035, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51660, 19670, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51661, 21172, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51662, 23445, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51663, 23641, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51664, 23642, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51665, 29848, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51666, 29849, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'Wun T "The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia ." Ann Intern Med 118 (1993):  318-9|Balmer CM "Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2." DICP 25 (1991):  490-8|Momin F, Kraut M, Lattin P, Valdivieso M "Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC) (meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 11 (1992):  a983|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|Kawachi Y, Watanabe A, Uchida T, Yoshizawa K, Kurooka N, Setsu K "Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor." Br J Haematol 94 (1996):  413-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51667, 13308, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51668, 19035, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51669, 19670, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51670, 21172, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51671, 23445, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51672, 23641, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51673, 23642, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51674, 29848, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51675, 29849, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51676, 13308, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51677, 19035, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51678, 19670, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51679, 21172, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51680, 23445, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51681, 23641, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51682, 23642, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51683, 29848, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51684, 29849, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', '"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51685, 24890, 'Aminolevulinic acid (topical)', 'Porphyrias', 'Photoactivation following topical application of aminolevulinic acid topical gel occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX, a photoactive compound which accumulates in the skin.  Therapy with aminolevulinic acid topical gel increases photosensitivity and it may cause uncontrolled phototoxic effects.  Its use in contraindicated in patients with porphyria or photodermatoses.', '3', '"Product Information. Levulan Kerastick (aminolevulinic acid)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51686, 24890, 'Aminolevulinic acid (topical)', 'Hemorrhage', 'The use of aminolevulinic acid topical gel increases the risk of bleeding in patients with coagulation disorders.  Care should be exercised during lesion preparation to avoid bleeding.', '2', '"Product Information. Levulan Kerastick (aminolevulinic acid)." Berlex Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51687, 5457, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51688, 23407, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51689, 5457, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51690, 23407, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', '"Product Information. Urispas (flavoxATE)." SmithKline Beecham', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51691, 291, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51692, 292, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51693, 293, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51694, 383, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51695, 384, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51696, 385, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51697, 4719, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51698, 4720, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51699, 4721, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51700, 4853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51701, 4854, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51702, 4857, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51703, 6172, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51704, 7761, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51705, 7762, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51706, 11246, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51707, 11247, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51708, 11248, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51709, 11589, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51710, 13777, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51711, 13778, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51712, 13792, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51713, 18855, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51714, 18856, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51715, 18862, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51716, 18863, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51717, 18864, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51718, 19024, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51719, 19025, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51720, 19027, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51721, 19029, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51722, 19030, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51723, 21853, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51724, 24263, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51725, 24264, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51726, 25712, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51727, 25713, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51728, 26547, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51729, 26548, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51730, 32786, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', '"Product Information. Allegra (fexofenadine)." Hoechst Marion Roussel  (2001):|Russell T, Stoltz M, Weir S "Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers." Clin Pharmacol Ther 64 (1998):  612-21', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51731, 6486, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51732, 14290, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51733, 19135, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51734, 31966, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51735, 6486, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51736, 14290, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51737, 19135, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51738, 31966, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51739, 6486, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51740, 14290, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51741, 19135, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51742, 31966, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', '"Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51743, 0, 'Floxuridine', 'Dihydropyrimidine Dehydrogenase Deficiency', 'An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP.  However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU.  5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase.   FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51744, 0, 'Floxuridine', 'Infections', 'The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases.  FUDR can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51745, 0, 'Floxuridine', 'Malnutrition', 'Floxuridine therapy is contraindicated for patients in a poor nutritional state.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51746, 0, 'Floxuridine', 'Bone Marrow Failure Disorders', 'The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression.  FUDR induces myelosuppression at recommended dosages.  Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51747, 0, 'Floxuridine', 'Stomatitis', 'Floxuridine induces stomatitis within the gastrointestinal tract.  Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.', '3', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51748, 0, 'Floxuridine', 'Hemorrhagic Disorders', 'Floxuridine (FUDR) induces myelosuppression.  Therapy with FUDR should be administered cautiously in patients with bleeding tendencies.  Therapy with FUDR should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.', '2', '"Product Information. FUDR (floxuridine)." Roche Laboratories  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51749, 0, 'Flunisolide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51750, 0, 'Flunisolide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51751, 0, 'Flunisolide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51752, 0, 'Flunisolide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51753, 0, 'Flunisolide', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51754, 347, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51755, 682, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51756, 785, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51757, 1992, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51758, 3542, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51759, 3663, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51760, 3664, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51761, 3665, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51762, 3666, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51763, 3667, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51764, 4360, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51765, 4960, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51766, 4993, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51767, 4994, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51768, 5203, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51769, 8612, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51770, 11598, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51771, 12546, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51772, 13070, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51773, 13446, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51774, 13531, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51775, 14067, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51776, 14150, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51777, 14151, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51778, 14152, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51779, 15757, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51780, 17257, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51781, 17642, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51782, 19147, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51783, 19201, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51784, 19202, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51785, 19208, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51786, 21162, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51787, 23321, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51788, 23322, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51789, 23323, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51790, 23324, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51791, 27679, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51792, 28496, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51793, 28497, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51794, 28730, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51795, 31820, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51796, 32275, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51797, 33255, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990):  565|Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990):  877-916|Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991):  585-6|Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991):  1020-1|Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992):  111-2|Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994):  188-90|Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994):  1177-81|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):|Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995):  641-7|Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996):  165-8', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51798, 347, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51799, 682, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51800, 785, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51801, 1992, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51802, 3542, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51803, 3663, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51804, 3664, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51805, 3665, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51806, 3666, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51807, 3667, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51808, 4360, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51809, 4960, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51810, 4993, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51811, 4994, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51812, 5203, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51813, 8612, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51814, 11598, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51815, 12546, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51816, 13070, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51817, 13446, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51818, 13531, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51819, 14067, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51820, 14150, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51821, 14151, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51822, 14152, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51823, 15757, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51824, 17257, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51825, 17642, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51826, 19147, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51827, 19201, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51828, 19202, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51829, 19208, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51830, 21162, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51831, 23321, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51832, 23322, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51833, 23323, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51834, 23324, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51835, 27679, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51836, 28496, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51837, 28497, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51838, 28730, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51839, 31820, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51840, 32275, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51841, 33255, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51842, 347, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51843, 682, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51844, 785, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51845, 1992, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51846, 3542, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51847, 3663, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51848, 3664, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51849, 3665, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51850, 3666, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51851, 3667, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51852, 4360, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51853, 4960, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51854, 4993, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51855, 4994, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51856, 5203, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51857, 8612, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51858, 11598, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51859, 12546, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51860, 13070, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51861, 13446, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51862, 13531, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51863, 14067, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51864, 14150, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51865, 14151, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51866, 14152, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51867, 15757, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51868, 17257, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51869, 17642, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51870, 19147, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51871, 19201, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51872, 19202, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51873, 19208, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51874, 21162, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51875, 23321, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51876, 23322, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51877, 23323, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51878, 23324, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51879, 27679, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51880, 28496, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51881, 28497, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51882, 28730, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51883, 31820, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51884, 32275, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51885, 33255, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992):  667-70|Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51886, 347, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51887, 682, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51888, 785, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51889, 1992, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51890, 3542, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51891, 3663, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51892, 3664, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51893, 3665, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51894, 3666, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51895, 3667, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51896, 4360, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51897, 4960, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51898, 4993, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51899, 4994, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51900, 5203, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51901, 8612, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51902, 11598, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51903, 12546, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51904, 13070, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51905, 13446, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51906, 13531, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51907, 14067, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51908, 14150, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51909, 14151, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51910, 14152, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51911, 15757, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51912, 17257, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51913, 17642, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51914, 19147, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51915, 19201, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51916, 19202, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51917, 19208, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51918, 21162, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51919, 23321, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51920, 23322, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51921, 23323, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51922, 23324, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51923, 27679, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51924, 28496, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51925, 28497, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51926, 28730, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51927, 31820, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51928, 32275, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51929, 33255, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990):  221-6|Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993):  10-27|"Product Information. Diflucan (fluconazole)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51930, 5621, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51931, 5622, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51932, 5623, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51933, 5624, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51934, 5625, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51935, 5626, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51936, 6601, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51937, 17469, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51938, 17470, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51939, 17471, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51940, 17472, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51941, 17473, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51942, 17474, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51943, 17475, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51944, 17476, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51945, 17477, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51946, 17479, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51947, 17480, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51948, 17484, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51949, 17488, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51950, 17500, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51951, 17501, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51952, 17502, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51953, 17503, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51954, 17504, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51955, 17505, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51956, 17506, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51957, 17507, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51958, 17510, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51959, 19908, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51960, 19909, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51961, 19910, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51962, 19912, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51963, 19913, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51964, 19914, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51965, 19915, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51966, 19916, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51967, 19917, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51968, 19918, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51969, 19919, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51970, 19920, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51971, 19921, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51972, 19922, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51973, 19923, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51974, 19924, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51975, 19925, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51976, 19927, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51977, 19928, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51978, 19929, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51979, 19930, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51980, 19931, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51981, 19932, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51982, 19933, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51983, 19934, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51984, 19935, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51985, 19936, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51986, 19937, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51987, 19938, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51988, 19939, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51989, 19940, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51990, 19941, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51991, 32919, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51992, 0, 'Flucytosine', 'Bone Marrow Failure Disorders', 'Flucytosine may frequently cause bone marrow toxicity, which can be irreversible and fatal in immunosuppressed patients.  Flucytosine should be used with extreme caution in patients with preexisting bone marrow suppression.  Frequent blood counts are recommended.', '3', 'Record CO, Skinner JM, Sleight P, Speller DC "Candida endocarditis treated with 5-fluorocytosine." Br Med J 01/30/71 (1971):  262-4|Harder EJ, Hermans PE "Treatment of fungal infections with flucytosine." Arch Intern Med 135 (1975):  231-7|Wise GJ, Goldberg P, Kozinn PJ, Nawabi IU "Agranulocytosis associated with flucytosine for urinary candidiasis." Urology 8 (1976):  490-1|Kauffman CA, Frame PT "Bone marrow toxicity associated with 5-fluorocytosine therapy." Antimicrob Agents Chemother 11 (1977):  244-7|Bennett JE, Dismukes WE, Duma RJ, et al. "A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis." N Engl J Med 301 (1979):  126-31|Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987):  236-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51993, 0, 'Flucytosine', 'Kidney Diseases', 'Flucytosine must be given with extreme caution to patients with impaired renal function.  Flucytosine is excreted primarily by the kidneys, and renal impairment may lead to accumulation of the drug.  Serum concentrations of the drug should be monitored to determine the adequacy of renal excretion in such patients.  Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug.  Close monitoring of renal, hematologic and hepatic function in all patients is recommended.', '3', 'Wade DN, Sudlow G "The kinetics of 5-fluorocytosine elimination in man." Aust N Z J Med 2 (1972):  153-8|Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973):  408-14|Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973):  382-4|Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973):  321-36|Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978):  333-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):|Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995):  327-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51994, 0, 'Flucytosine', 'Diseases requiring hemodialysis', 'Flucytosine is substantially removed by hemodialysis and should be administered after dialysis.', '2', 'Drouhet E, Babinet P, Chapusot JP, Kleinknecht D "5-fluorocytosine in the treatment of candidiasis with acute renal insufficiency." Biomedicine 19 (1973):  408-14|Dawborn JK, Page MD, Schiavone DJ "Use of 5-fluorocytosine in patients with impaired renal function." Br Med J 11/17/73 (1973):  382-4|Schonebeck J, Polak A, Fernex M, Scholer HJ "Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function." Int J Exp Clin Chemother 18 (1973):  321-36|Cutler RE, Blair AD, Kelly MR "Flucytosine kinetics in subjects with normal and impaired renal function." Clin Pharmacol Ther 24 (1978):  333-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):|Lau AH, Kronfol NO "Elimination of flucytosine by continuous hemofiltration." Am J Nephrol 15 (1995):  327-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51995, 0, 'Flucytosine', 'Hypokalemia', 'Flucytosine may cause hypokalemia.  Patients with preexisting hypokalemia should be monitored closely for worsening electrolyte disturbances during therapy with flucytosine.', '2', 'Stamm AM, Diasio RB, Dismukes WE, et al. "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987):  236-42|"Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51996, 17327, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51997, 17328, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51998, 17329, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51999, 26475, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (52000, 26476, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', '"Product Information. Paser D/R (aminosalicylic acid)." Jacobus Pharmaceutical Company', 'DDInter', 0);
